SCHEMBL247607

SCHEMBL247607

CCC(N)(CC)C1CCNCC1

nearest known ligand 0.35

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ARG1 P05089 1/20 0.35
ARG2 P78540 1/20 0.35
GABRA1 P14867 1/20 0.33
GABRG2 P18507 1/20 0.33
GABRB3 P28472 1/20 0.33
MEN1 O00255 1/20 0.31
LMNA P02545 1/20 0.31
CYP2D6 P10635 1/20 0.31
HRH1 P35367 1/20 0.31
SCN1A P35498 1/20 0.31
KMT2A Q03164 1/20 0.31
SCN2A Q99250 1/20 0.31
SCN3A Q9NY46 1/20 0.31
KCNH2 Q12809 1/20 0.31
GNAO1 P09471 3/20 0.31
GNAI3 P08754 2/20 0.31
GNAI1 P63096 2/20 0.31
NOS2 P35228 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL6150114 0.98 ARG1 (0.34) ARG1ARG2GABRA1GABRG2GABRB3
SCHEMBL13640032 0.77 CYP1A2 (0.33)
SCHEMBL5650003 0.77 GBA1 (0.45) GABRA1GABRG2GABRB3MEN1LMNA
SCHEMBL1030996 0.75 CYP1A2 (0.37) MEN1LMNAKMT2A
SCHEMBL13930811 0.73 MEN1 (0.32) GABRA1GABRG2GABRB3MEN1LMNA
SCHEMBL14212686 0.73 KDM4E (0.39) GABRA1GABRG2GABRB3MEN1LMNA
SCHEMBL1088624 0.72 ALDH1A1 (0.46) ARG1ARG2MEN1LMNACYP2D6
SCHEMBL6945067 0.71 LMNA (0.39) ARG1ARG2GABRA1GABRG2GABRB3
SCHEMBL89947 0.71
SCHEMBL3285306 0.71

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2842942-B1 TRANS-2-DECENOIC ACID DERIVATIVE AND DRUG CONTAINING SAME NIPPON ZOKI PHARMACEUTICAL CO (JP) 2016-12-07 EP disclosed
US-9428477-B2 Trans-2-decenoic acid derivative and drug containing same NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) 2016-08-30 US disclosed
EP-2188251-B1 ARYLSULFONAMIDES WITH ANALGESIC ACTIVITY BOEHRINGER INGELHEIM INT (DE) 2015-04-29 EP disclosed
US-20150087823-A1 TRANS-2-DECENOIC ACID DERIVATIVE AND DRUG CONTAINING SAME NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) 2015-03-26 US disclosed
EP-2842942-A1 TRANS-2-DECENOIC ACID DERIVATIVE AND DRUG CONTAINING SAME Nippon Zoki Pharmaceutical Co., Ltd. (JP) 2015-03-04 EP disclosed
EP-2061779-B1 ARYL SULFONAMIDES WITH AN ANALGESIC ACTION BOEHRINGER INGELHEIM INT (DE) 2013-11-06 EP disclosed
US-8450306-B2 Bradykinin B1-receptor antagonists BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-05-28 US disclosed
EP-2402329-B1 Analgetic phenylsulphonamides BOEHRINGER INGELHEIM INT (DE) 2013-05-22 EP disclosed
US-8252785-B2 Aryl sulfonamides as bradykinin-B1-receptor antagonists BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-08-28 US disclosed
EP-2402329-A1 Analgetic phenylsulphonamides Boehringer Ingelheim International GmbH (DE) 2012-01-04 EP disclosed
EP-2284166-A1 Arylsulfonamides with analgetic activity Boehringer Ingelheim International GmbH (DE) 2011-02-16 EP disclosed
US-20110021488-A1 New Compounds BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-01-27 US disclosed
US-7858618-B2 Compounds BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-12-28 US disclosed
EP-2188251-A1 ARYLSULFONAMIDES WITH ANALGESIC ACTIVITY Boehringer Ingelheim International GmbH (DE) 2010-05-26 EP disclosed
US-20090137545-A1 Compounds BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-05-28 US disclosed
EP-2061779-A1 ARYL SULFONAMIDES WITH AN ANALGESIC ACTION Boehringer Ingelheim International GmbH (DE) 2009-05-27 EP disclosed
WO-2009021758-A1 ARYLSULFONAMIDES HAVING AN ANALGESIC EFFECT BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-02-19 WO disclosed
WO-2009021946-A1 NOVEL COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-02-19 WO disclosed
EP-2025675-A1 Arylsulfonamides with analgetic activity Boehringer Ingelheim International GmbH (DE) 2009-02-18 EP disclosed
WO-2008022945-A1 ARYL SULFONAMIDES WITH AN ANALGESIC ACTION BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2008-02-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090137545-A1 Compounds ADORA2B, ABCB11, CYP11B1 ARG1 250/4885ARG2 468/4885GABRA1 261/4885
US-20110021488-A1 New Compounds ABCG2, ADORA2B, ADORA3 ARG1 288/4885ARG2 491/4885GABRA1 155/4885
US-20150087823-A1 TRANS-2-DECENOIC ACID DERIVATIVE AND DRUG CONTAINING SAME GAP43, BDNF, PARK7 ARG1 2381/4885ARG2 1129/4885GABRA1 910/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.